148 related articles for article (PubMed ID: 25322975)
21. [Hormone replacement therapy and venous thromboembolism].
Pavičić Baldani D; Skrgatić L; Simunić V; Elvedi Gasparović V; Geršak B
Lijec Vjesn; 2015; 137(1-2):34-40. PubMed ID: 25906547
[TBL] [Abstract][Full Text] [Related]
22. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
[TBL] [Abstract][Full Text] [Related]
23. Hormone replacement therapy: controversies, pros and cons.
Warren MP; Halpert S
Best Pract Res Clin Endocrinol Metab; 2004 Sep; 18(3):317-32. PubMed ID: 15261840
[TBL] [Abstract][Full Text] [Related]
24. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal.
Caufriez A
Ann Endocrinol (Paris); 2007 Sep; 68(4):241-50. PubMed ID: 17651686
[TBL] [Abstract][Full Text] [Related]
25. [Thrombophilic syndrome associated to phenotypic resistance to activated protein C in postmenopausal women].
Caserta L; Caserta R; Torella M; Perricone F; Nesti E; Sessa M; Tagliaferri A; De Francesco F; De Lucia D; Panariello S
Minerva Ginecol; 2004 Apr; 56(2):131-6. PubMed ID: 15258541
[TBL] [Abstract][Full Text] [Related]
26. Hormone replacement therapy and prevention of chronic conditions.
Gambacciani M; Cagnacci A; Lello S
Climacteric; 2019 Jun; 22(3):303-306. PubMed ID: 30626218
[TBL] [Abstract][Full Text] [Related]
27. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
Ettinger B; Pressman A
Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
[TBL] [Abstract][Full Text] [Related]
28. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
Trémollieres FA; Pouilles JM; Ribot C
Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials.
Komm BS; Thompson JR; Mirkin S
Climacteric; 2015; 18(4):503-11. PubMed ID: 25511453
[TBL] [Abstract][Full Text] [Related]
30. [From the Cochrane Library: postmenopausal hormone replacement therapy (HRT) does not protect women against cardiovascular disease but does lead to an increased risk of venous thromboembolism].
Hamerlynck JV; Middeldorp S; Scholten RJ
Ned Tijdschr Geneeskd; 2006 Mar; 150(10):546-8. PubMed ID: 16566418
[TBL] [Abstract][Full Text] [Related]
31. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
[TBL] [Abstract][Full Text] [Related]
32. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
33. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
Koledova VV; Khalil RA
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy.
Rosano G; Vitale C; Spoletini I; Fini M
Climacteric; 2012 Aug; 15(4):299-305. PubMed ID: 22424090
[TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy in the aged. A state of the art review.
Jacobs S; Hillard TC
Drugs Aging; 1996 Mar; 8(3):193-213. PubMed ID: 8720745
[TBL] [Abstract][Full Text] [Related]
36. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism.
Renoux C; Dell'Aniello S; Brenner B; Suissa S
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):554-560. PubMed ID: 28326633
[TBL] [Abstract][Full Text] [Related]
37. Hormone replacement therapy and venous thromboembolism.
Eisenberger A; Westhoff C
J Steroid Biochem Mol Biol; 2014 Jul; 142():76-82. PubMed ID: 24007716
[TBL] [Abstract][Full Text] [Related]
38. Effects of transdermal and oral hormone replacement therapies on monocyte chemoattractant protein-1 levels: a randomized clinical trial.
Taşçı T; Şükür YE; Özmen B; Atabekoğlu CS; Cengiz SD; Koçbulut E; Berker B; Sönmezer M
Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():50-4. PubMed ID: 24655552
[TBL] [Abstract][Full Text] [Related]
39. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
L'hermite M; Simoncini T; Fuller S; Genazzani AR
Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
[TBL] [Abstract][Full Text] [Related]
40. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
Speroff L
Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
